Soretolide (Laboratoires Biocodex).
Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials [299344]. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures [299344]. The company is currently discussing future development plans for this drug [410625].
Fatope
M O
MO
Sultan Quaboos University, Chemistry Dept College of Science, Ai-Khod, Sultanate of Oman. majek@squ.edu.om
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000075202:Contraindications; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
D000927:Anticonvulsants; D007555:Isoxazoles; C105493:soretolide